ARTICLE | Product Development
Neurimmune launches CV trial, first clinical antibody program outside the brain
February 27, 2020 1:29 PM UTC
As the first antibody out of Neurimmune’s reverse translation platform -- aducanumab -- heads for FDA submission this year, the biotech is looking beyond its core focus in CNS diseases.
On Thursday, Neurimmune AG said it has enrolled the first patient in a Phase I trial of anti-TTR amyloid antibody NI006 to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM)...